Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
Keeping Track: A Quintet Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
New Trial With Longer Liver Elevation Needed For Iclaprim, US FDA Tells Motif Bio
Longer follow-up is part of regulatory path forward, the struggling antibiotics firm says after meeting with US FDA to discuss complete response letter.
Motif Plunges As FDA Demands New Iclaprim Study
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.